Your AI-Trained Oncology Knowledge Connection!


Video

Dr. Borgen on the Negative Effects of Pinkwashing

Dr. Patrick Borgen, from the Maimonides Breast Cancer Center, Discusses the Negative Effects of Pinkwashing

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the negative effects of “pinkwashing”, a process of making a product pink in order to gain from the association with breast cancer advocacy.

In recent years beast cancer research and funding has grown by leaps and bounds. Awareness and funding has been extraordinarily high due to the efforts of women advocating for each other and themselves. Successful advocacy campaigns have resulted in higher funding for clinical trials, which has led to breast cancer research being far ahead of other types of cancer.

Advocacy successes have not gone unnoticed and many companies have discovered that if you link a product to the cause it can increase sales. In many cases the company will give a portion of the revenue to a breast cancer organization. Initially this was very beneficial and bolstered funding but in recent years pinkwashing has gone overboard.

Many products that are unrelated, such as beer pong tables, KFC buckets, and even weaponry, have adopted the pink coloring. Borgen notes that after a certain point there is so many different pink items that it goes unnoticed. Pinkwashing results in consumers missing the point of the breast cancer cause, which lessens the impact of the entire campaign.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Timothy S. Fenske, MD, MS
Sheela Rao, MBBS, MD, FRCP
Yufei Liu, MD, PhD
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD
COOMBS
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute